EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Syros Pharmaceuticals Inc (SYRS) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Syros Pharmaceuticals Inc $0.00, price $0.00, upside -25.0%, quality 19 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US87184Q1076

SP Syros Pharmaceuticals Inc logo Thin data Sep 27, 2026

Syros Pharmaceuticals Inc

SYRS · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $0.0003 · Overvalued (−25.0%)
!Quality 19/100
!Weak Growth (revenue 5y +37.1 %/yr)
!Negative equity (buybacks among others) · negative free cash flow
!Mixed vs. peers (2/5)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Syros Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$56.60 $0.0001 Fair Value $0.0003 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.0001 – $56.60 · the $0.0004 price screens above the $0.0003 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Syros Pharmaceuticals in your weekly email

Every Wednesday you see whether Syros Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies.

Show more

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Syros Pharmaceuticals Inc (SYRS) currently trades at $0.0004, while our model-based Fair Value estimate is $0.0003, implying the stock looks roughly 33.3% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Syros Pharmaceuticals Inc reported revenue of $9.9M in FY2023 versus $2.0M in FY2019, a compound +49.6%/yr. Reported net income was −$165M in FY2023.

Key figures

Market cap $15.7K · P/S ratio 0.03 · EPS (TTM) $−3.07 · Return on equity −777% · Return on assets (EBIT) −55.4% · Operating margin −28,892% · Revenue growth (YoY) −3.3% · Free cash flow −$110M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).

What moves the price

The share trades about 92% below its 52-week high and 300% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −25%, SYRS screens richer than that median.

Fair Value models

Bear $0.0003 Fair Value $0.0003 Bull $0.0003
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0003 $0.0004 $0.0006 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.0003 $0.0004 $0.0006 54

Open the full fair value analysis →

Notify me when SYRS reaches fair value

Put SYRS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 19/100

Of which business quality 19 · Market factors (momentum, volatility) 43

Profitability 2
Margins and returns on capital today
Quality Growth 14
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 25
Balance sheet, leverage, solvency risk
Investment 99
Disciplined investing over empire-building
Low Volatility 53
Calm price path (market factor)
Momentum 60
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−33.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.1%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,136.4% (2018) → −1,298.2% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2023 is a loss year, no rate is defined from a loss
not computed

SYRS screens 33% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Syros Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 647 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 19 · Bottom 25%
Fair Value upside −25.0% · Above median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −59.9% · Bottom 25%
Growth and dividend
Revenue growth −3.3% · Below median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 0.04× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $526.19 $578.81 +10%
Regeneron Pharmaceuticals, Inc REGN $788.04 $1,275 +62%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$176.95 A$194.65 +10%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Syros Pharmaceuticals Inc · Fair Value
$0.0003 −33%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Syros Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/SYRS

Frequently asked questions

Is Syros Pharmaceuticals Inc (SYRS) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0003 versus a price of $0.0004, about −25% upside (overvalued).
What is the fair value of SYRS?
Our model-based fair value for Syros Pharmaceuticals Inc is $0.0003 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.0004.
What is the quality score of SYRS?
Syros Pharmaceuticals Inc has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Syros Pharmaceuticals Inc (SYRS)?
Our model-based price target is the fair value of $0.0003 (as of Sep 27, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Syros Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.0003, about −25% upside versus a price of $0.0004 (overvalued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of Syros Pharmaceuticals Inc (SYRS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Syros Pharmaceuticals Inc it is $0.0003 per share (as of Sep 27, 2026), against a price of $0.0004. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Syros Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, SYRS trades above its calculated fair value: price $0.0004, fair value $0.0003, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SYRS?
No. The price is what the market pays today ($0.0004); the fair value is what the company's own numbers justify ($0.0003). For Syros Pharmaceuticals Inc the two are $0.0001 per share apart. That gap is exactly why we show both numbers side by side.
How much is Syros Pharmaceuticals Inc worth?
The market values Syros Pharmaceuticals Inc at about $15.7K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0004; our models calculate a fair value of $0.0003 per share.
How solid is the balance sheet of Syros Pharmaceuticals Inc (SYRS)?
Balance-sheet figures for Syros Pharmaceuticals Inc (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 19/100, which measures business quality independently of the share price.
How far is SYRS from its 52-week high?
Syros Pharmaceuticals Inc trades at $0.0004, about 92% below its 52-week high of $0.0050 and 300% above the low of $0.0001 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0003 is for.
Which stocks are comparable to Syros Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Syros Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0004, calculated fair value $0.0003 (−25%), Quality Score 19/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SYRS calculated?
We run Syros Pharmaceuticals Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0003, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Syros Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Syros Pharmaceuticals Inc (SYRS)?
The closing price on Sep 25, 2026 was $0.0004. Our model-based fair value is $0.0003, about −25% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Syros Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($0.0003). The favourable scenario is already priced in. Weak quality (19/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Syros Pharmaceuticals Inc

How large is the market capitalisation of Syros Pharmaceuticals Inc (SYRS)?
The market capitalisation of Syros Pharmaceuticals Inc is $15.7K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Syros Pharmaceuticals Inc (SYRS)?
The price-to-sales ratio of Syros Pharmaceuticals Inc is 0.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Syros Pharmaceuticals Inc (SYRS)?
Earnings per share at Syros Pharmaceuticals Inc are $−3.07. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Syros Pharmaceuticals Inc (SYRS)?
The return on equity (ROE) of Syros Pharmaceuticals Inc is −777% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Syros Pharmaceuticals Inc (SYRS)?
On an EBIT basis the return on assets of Syros Pharmaceuticals Inc is −55.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Syros Pharmaceuticals Inc (SYRS)?
The operating margin of Syros Pharmaceuticals Inc is −28,892% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Syros Pharmaceuticals Inc (SYRS)?
Revenue at Syros Pharmaceuticals Inc is growing −3.3% versus a year earlier (3y avg −13.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Syros Pharmaceuticals Inc (SYRS) generate?
The free cash flow of Syros Pharmaceuticals Inc is −$110M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Syros Pharmaceuticals Inc (SYRS) hold?
Syros Pharmaceuticals Inc holds more cash than debt, $77.5M net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Syros Pharmaceuticals Inc in the live analysis

One click puts Syros Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.